GSK-257049/026

Study Sponsor: GSK

Study Title

A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years in a malaria-endemic region of Mozambique.

Medicine or Vaccine (generic name)

RTS,S Vaccine

Sponsor Identification Number

257049/026

Trial Registry Identification Number(#'s)

NCT00197041

Medical Condition

Malaria

Phase

Phase 2

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=257049/026

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00197041

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

A follow-on study 104297 was conducted. The analysis-ready data from this study is provided in combined datasets with the analysis-ready data from 104297. An annotated case report form is not available for this study. A blank case report form will be provided

Date Added to this Site

July 2014